Kirkland David, Zeiger Errol, Madia Federica, Gooderham Nigel, Kasper Peter, Lynch Anthony, Morita Takeshi, Ouedraogo Gladys, Parra Morte Juan Manuel, Pfuhler Stefan, Rogiers Vera, Schulz Markus, Thybaud Veronique, van Benthem Jan, Vanparys Philippe, Worth Andrew, Corvi Raffaella
Kirkland Consulting, PO Box 79, Tadcaster LS24 0AS, United Kingdom.
Errol Zeiger Consulting, 800 Indian Springs Rd., Chapel Hill, NC 27514, USA.
Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:55-68. doi: 10.1016/j.mrgentox.2014.10.005. Epub 2014 Oct 23.
Positive results in the Ames test correlate well with carcinogenic potential in rodents. This correlation is not perfect because mutations are only one of many stages in tumour development. Also, situations can be envisaged where the mutagenic response may be specific to the bacteria or the test protocol, e.g., bacterial-specific metabolism, exceeding a detoxification threshold, or the induction of oxidative damage to which bacteria may be more sensitive than mammalian cells in vitro or tissues in vivo. Since most chemicals are also tested for genotoxicity in mammalian cells, the pattern of mammalian cell results may help identify whether Ames-positive results predict carcinogenic or in vivo mutagenic activity. A workshop was therefore organised and sponsored by the EU Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) to investigate this further. Participants presented results from other genotoxicity tests with Ames-positive compounds. Data came from published, regulatory agency, and industry sources. The question was posed whether negative results in mammalian cell tests were associated with absence of carcinogenic or in vivo genotoxic activity despite a positive Ames test. In the limited time available, the presented data were combined and an initial analysis suggested that the association of negative in vitro mammalian cell test results with lack of in vivo genotoxic or carcinogenic activity could have some significance. Possible reasons why a positive Ames test may not be associated with in vivo activity and what additional investigations/tests might contribute to a more robust evaluation were discussed. Because a considerable overlap was identified among the different databases presented, it was recommended that a consolidated database be built, with overlapping chemicals removed, so that a more robust analysis of the predictive capacity for potential carcinogenic and in vivo genotoxic activity could be derived from the patterns of mammalian cell test results obtained for Ames-positive compounds.
艾姆斯试验的阳性结果与啮齿动物的致癌潜力密切相关。这种相关性并不完美,因为突变只是肿瘤发展众多阶段中的一个。此外,可以设想这样的情况,即诱变反应可能是细菌或测试方案所特有的,例如细菌特异性代谢、超过解毒阈值或诱导氧化损伤,而细菌在体外可能比哺乳动物细胞更敏感,在体内可能比哺乳动物组织更敏感。由于大多数化学物质也会在哺乳动物细胞中进行基因毒性测试,哺乳动物细胞测试的结果模式可能有助于确定艾姆斯试验阳性结果是否预示着致癌或体内诱变活性。因此,由欧盟替代动物试验参考实验室(EURL ECVAM)组织并赞助了一次研讨会,以进一步研究这一问题。参与者展示了对艾姆斯试验阳性化合物进行的其他基因毒性测试的结果。数据来自已发表的、监管机构和行业来源。提出的问题是,尽管艾姆斯试验呈阳性,但哺乳动物细胞测试中的阴性结果是否与无致癌或体内基因毒性活性相关。在有限的时间内,对所展示的数据进行了汇总,初步分析表明,体外哺乳动物细胞测试阴性结果与缺乏体内基因毒性或致癌活性之间的关联可能具有一定意义。讨论了艾姆斯试验阳性可能与体内活性无关的可能原因,以及哪些额外的调查/测试可能有助于进行更可靠的评估。由于在所展示的不同数据库之间发现了相当多的重叠,因此建议建立一个合并数据库,去除重叠的化学物质,以便从艾姆斯试验阳性化合物的哺乳动物细胞测试结果模式中得出对潜在致癌和体内基因毒性活性预测能力的更可靠分析。